Top Medical News
Pearl Toh, 6 hours ago
Young, healthy individuals at low risk for atherosclerotic cardiovascular disease (ASCVD) events may still face a heightened lifetime risk of death from CV events if they have elevated LDL-C levels of ≥160 mg/dL, reveal the CCLS*.
7 hours ago
Mirabegron, a β3-adrenoreceptor agonist, poses no increased cardiovascular risk when used as treatment for overactive bladder syndrome, a new study has found.
Roshini Claire Anthony, 11 hours ago

The combination of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) more than doubled progression-free survival (PFS) as well as improved overall survival (OS) in patients with CD30-expressing peripheral T-cell lymphoma compared with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), according to results of the phase III ECHELON-2* trial.

11 hours ago
Intensive statin therapy in the secondary prevention of ischaemic stroke or transient ischaemic attack significantly increases the risk of premature discontinuation as compared with a moderate intensity, a study has found.
12 hours ago
A feasibility study has recently shown that individualized breathlessness intervention significantly lowers dyspnoea scores in patients with severe chronic obstructive pulmonary disease (COPD) and refractory breathlessness, with high levels of patient acceptability.
Stephen Padilla, 13 hours ago
Sonographic patterns outlined by three guidelines (the 2015 American Thyroid Association [ATA] Management Guidelines, the 2014 British Thyroid Association [BTA] Guidelines for the Management of Thyroid Cancer and the Thyroid Imaging Reporting and Data System TIRADS]) have high sensitivity and negative predictive value (NPV), which are needed for triaging of thyroid nodules for subsequent fine needle aspiration (FNA), according to a Singapore study.
Jairia Dela Cruz, 14 hours ago
The use of the PARP inhibitor olaparib in the maintenance setting confers notable gains in progression-free survival in women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, according to data from the phase III SOLO1 trial.
Special Reports
30 Nov 2018
Despite risk factors for cardiovascular disease (CVD) being similar around the world, the burden of CVD is not uniform across nations. Furthermore, CVD-related death in low- to middle-income countries (LMICs) has increased by two-thirds in the last 30 years, and now account for a whopping 80% of global deaths due to CVD.
30 Nov 2018
Poor adherence to statin therapy is leaving many patients with dyslipidaemia at high risk of potentially life-threatening cardiovascular events. Statins are the current standard of care for reducing the risk of cardiovascular disease in these patients and for improving life expectancy, with possible economic benefits for healthcare systems too. However, many patients with dyslipidaemia are not achieving or maintaining treatment targets because they fail to stick to their prescribed statin therapy. An article co-authored by lipidologist Peter Lansberg, and published in Vascular Health and Risk Management, considers this issue and reviews approaches to overcome non-adherence.
28 Nov 2018
At the recent 22nd Malaysian Conference of Psychological Medicine, Dr Hazli Zakaria spoke on the importance of early optimized treatment in improving treatment outcomes in patients with major depressive disorder (MDD).
28 Nov 2018
At the Abbott-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congres sat Hilton Kuala Lumpur, Dr Zanariah Hussein shared her insights into the important role of an emerging marker of hypercholesterolaemia, and its relationship with cardiovascular (CV) and diabetic retinopathy (DR) risks.
27 Nov 2018
Through a cardiology webcast co-hosted by Pfizer, the National Heart Association of Malaysia (NHAM), and the American College of Cardiology (ACC), Dr Ong Mei Lin, Dr Aaron D. Kugelmass and Dr Tracy Wang shared their insights into the importance of secondary prevention measures in reducing the burden of atherosclerotic cardiovascular disease (ASCVD).
21 Nov 2018
At the AstraZeneca-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congress at Hilton Kuala Lumpur, Professor Ronald Ma highlighted the role of a novel combination therapy in reducing HbA1c levels while simultaneously providing cardiovascular (CV) protection to improve patient outcomes.
21 Nov 2018
In conjunction with the launch of Dymista® in Malaysia, Mylan convened a symposium which saw distinguished speakers addressing the allergic rhinitis (AR) landscape in the country and the latest developments in treatment options.
Conference Reports
Elaine Soliven, 10 Dec 2018
Treatment with luspatercept, a first-in-class erythroid maturation agent, significantly achieves red blood cell transfusion independence (RBC-TI) in patients with anaemia who had low-risk myelodysplastic syndrome (MDS) with ring sideroblasts (RS), according to results of the MEDALIST* trial presented at ASH 2018.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Roshini Claire Anthony, 07 Dec 2018

Findings from the updated analysis of the phase III MURANO* trial solidify the role of fixed-dose venetoclax plus rituximab in a majority of patients with relapsed/refractory chronic lymphocytic leukaemia (CLL).

Elvira Manzano, 07 Dec 2018
Systemic administration of the gene therapy scAAV2/8-LP1-hFIXco to patients with severe haemophilia B led to stable therapeutic expression of the factor IX gene over 8 years without evidence of late toxicities from treatment, according to a long-term follow-up study.
Elvira Manzano, 05 Dec 2018
Apalutamide, added to standard treatment with androgen deprivation therapy (ADT), provides comparable clinical benefits among Asian vs non-Asian patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), according to a subset analysis of the phase III SPARTAN study.
Elaine Soliven, 05 Dec 2018

Treatment with ramucirumab, a human IgG1 monoclonal antibody, significantly improves overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) in both Asians and non-Asians, based on a pooled analysis of REACH* and REACH-2** studies presented at ESMO Asia 2018.

Jairia Dela Cruz, 05 Dec 2018
Beta blockers and/or renin-angiotensin inhibitors appear to be useful for preventing cardiotoxicity from anthracycline exposure, according to the results of a systematic review and meta-analysis presented at the European Society for Medical Oncology (ESMO) Asia 2018 Congress.
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download